Oncology Pharmacists Lead Biosimilar Integration Strategies to Optimize Cancer Care Access and Costs
核心洞察
Biosimilar substitution is most effective when implemented at the start of new treatment regimens, with nearly 80% of physicians reporting comfort switching stable patients from reference biologics to biosimilars (搜索).
Medically integrated dispensing models enable pharmacists to align drug dispensing with evidence-based pathways and payer preferences in real-time, reducing delays and improving treatment consistency.
505(b)(2) drugs (搜索) present unique operational challenges as they are not therapeutically equivalent to reference products and require separate billing codes and prior authorization processes.
Oncology pharmacists are emerging as key leaders in the successful integration of biosimilars (搜索) and 505(b)(2) drugs (搜索) into cancer (搜索) care, addressing complex operational and clinical challenges while optimizing patient access to cost-effective therapies. At the 2025 Advanced Topics for Oncology Pharmacy Professionals Summit in Salt Lake City, Utah, experts outlined strategic approaches to navigate the evolving landscape of these alternative therapies.
Laura R. Bobolts, PharmD, BCOP, senior vice president of clinical strategy and growth at OncoHealth (搜索), emphasized that biosimilar substitution achieves optimal results when implemented at treatment initiation rather than mid-therapy. "More commonly, preferred biosimilars (搜索) are requested to be substituted up front when starting a new treatment," Bobolts explained. "This helps minimize disruption to workflows."
Regulatory Framework Shapes Substitution Strategies
Current Medicare (搜索) regulations restrict step therapy involving biosimilars (搜索) to new treatment starts, while commercial payers maintain greater flexibility to encourage mid-treatment substitutions. This regulatory distinction influences how healthcare systems approach biosimilar implementation strategies.
Supporting physician confidence in biosimilar adoption, a survey by the Alliance for Safe Biologic Medicines (搜索) revealed that nearly 80% of physicians reported feeling at least somewhat comfortable switching stable patients from a reference biologic to a biosimilar. This data underscores growing clinical acceptance of these therapeutic alternatives.
Payer-Provider Collaboration Drives Success
Effective biosimilar implementation requires strategic coordination between payers and providers. Bobolts recommended that payers select multiple preferred biosimilars (搜索) or 505(b)(2) drugs (搜索) to increase alignment with provider formularies and reduce implementation friction.
"It's also helpful for a payer to evaluate the prescribing patterns of their providers in advance," Bobolts noted. "This ensures that preferred products already match the market's utilization and are as least disruptive as possible."
Healthcare providers should familiarize themselves with common formularies and payer preferences within their patient populations to ensure appropriate drug selection from treatment initiation, thereby reducing delays in care, coverage, or reimbursement.
Performance Metrics Beyond Utilization Rates
Healthcare systems are implementing comprehensive metrics to evaluate biosimilar adoption success beyond simple utilization tracking. Key performance indicators include the rate of up-front changes to preferred products, frequency of denials related to nonpreferred usage, and practice-level responsiveness to formulary education efforts.
"Some providers are highly responsive and align quickly, while others may require additional education," Bobolts observed. "Understanding these trends can help target interventions and streamline transitions more effectively."
505(b)(2) Products Present Unique Challenges
Unlike traditional generics, 505(b)(2) drugs (搜索) represent new drug applications that rely partly on existing clinical data while maintaining distinct operational complexities. These products cannot be automatically substituted and require individual billing codes and reimbursement pathways.
"Each 505(b)(2) product is treated as a unique entity, often with its own billing code, prior authorization requirements, and reimbursement pathway," Bobolts explained. This creates administrative burden when multiple 505(b)(2) products are used to manage supply constraints or cost considerations.
Naming conventions further complicate implementation, as some products carry proprietary names while others are referred to by manufacturer, contributing to confusion in prescribing and coverage decisions.
Medically Integrated Dispensing Optimizes Implementation
Medically integrated dispensing (MID), where pharmacy services are embedded within oncology clinics, has emerged as a best practice for managing biosimilars (搜索) and 505(b)(2) therapies. This model enables real-time alignment of drug dispensing with evidence-based institutional pathways and payer preferences.
"Pharmacists in MID settings can help build EHR [electronic health record] treatment order sets using preferred drugs, educate providers and patients, and manage inventory proactively to prevent supply-related variation," Bobolts detailed. This hands-on approach promotes treatment consistency and reduces delays associated with prior authorization or reimbursement issues.
Financial Navigation Complexities
Patient assistance programs (PAPs) and manufacturer co-pay support vary significantly across product categories. Originator biologics typically offer the most robust support, while biosimilars (搜索) provide more limited assistance. Support for 505(b)(2) drugs (搜索) is often minimal, as they are already marketed as cost-saving alternatives.
"If a patient qualifies for a PAP for one product but the provider prefers another, the patient may need to be reenrolled in a new program, if one is even available," Bobolts warned, highlighting the importance of coordinated financial navigation.
Cross-Team Coordination Streamlines Access
Pharmacists serve as crucial bridges between clinical and administrative teams, ensuring efficient implementation of generic, biosimilar, and 505(b)(2) therapies. Proactive collaboration with revenue cycle and prior authorization teams helps align with payer formularies and avoid unnecessary delays.
"By learning the preferred drugs for each payer, pharmacists can help ensure the right product is selected up front, avoiding unnecessary denials or delays due to mismatched coverage," Bobolts emphasized.
Future Regulatory Considerations
Looking toward regulatory improvements, Bobolts identified therapeutic interchangeability as an ideal solution for streamlining adoption. "In my dream world, all biosimilars (搜索) and 505(b)(2) drugs (搜索) would be therapeutically interchangeable with the reference product," she explained.
Such policy shifts could enable automatic substitution, reduce administrative burden, increase competition, and ultimately lower costs, mirroring efficiencies seen with traditional generics. While current regulatory frameworks do not permit this level of interchangeability, ongoing discussions suggest potential future progress in this area.